- Home
- FRES vs CHRO Comparison
FRES vs CHRO Comparison
Compare FRES & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRES
- CHRO
- Stock Information
- Founded
- FRES 2010
- CHRO 2002
- Country
- FRES United States
- CHRO United States
- Employees
- FRES N/A
- CHRO N/A
- Industry
- FRES Medical Specialities
- CHRO
- Sector
- FRES Health Care
- CHRO
- Exchange
- FRES Nasdaq
- CHRO Nasdaq
- Market Cap
- FRES 6.4M
- CHRO 6.7M
- IPO Year
- FRES 2020
- CHRO 2024
- Fundamental
- Price
- FRES $1.85
- CHRO $0.95
- Analyst Decision
- FRES
- CHRO Strong Buy
- Analyst Count
- FRES 0
- CHRO 1
- Target Price
- FRES N/A
- CHRO N/A
- AVG Volume (30 Days)
- FRES 4.8K
- CHRO 12.3K
- Earning Date
- FRES 09-17-2024
- CHRO 08-13-2024
- Dividend Yield
- FRES N/A
- CHRO N/A
- EPS Growth
- FRES N/A
- CHRO N/A
- EPS
- FRES N/A
- CHRO N/A
- Revenue
- FRES $2,341,326.00
- CHRO N/A
- Revenue This Year
- FRES N/A
- CHRO N/A
- Revenue Next Year
- FRES N/A
- CHRO N/A
- P/E Ratio
- FRES N/A
- CHRO N/A
- Revenue Growth
- FRES 94.50
- CHRO N/A
- 52 Week Low
- FRES $1.55
- CHRO $0.59
- 52 Week High
- FRES $26.00
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- FRES 43.57
- CHRO N/A
- Support Level
- FRES $1.58
- CHRO N/A
- Resistance Level
- FRES $2.01
- CHRO N/A
- Average True Range (ATR)
- FRES 0.17
- CHRO 0.00
- MACD
- FRES 0.05
- CHRO 0.00
- Stochastic Oscillator
- FRES 62.50
- CHRO 0.00
About FRES Fresh2 Group Limited
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.
About CHRO Chromocell Therapeutics Corporation
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.